Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

ImmunityBio (IBRX) announced U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s ...

ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's ...

Upon securing FDA approval, ImmunityBio, Inc. (NASDAQ:IBRX) said supplies of rBCG would be shipped immediately. The ...

Credit: ImmunityBio. Developed by the Serum Institute of India, the rBCG product, which has been modified to improve its immunogenicity and safety, was evaluated in phase 1/2 clinical trials in ...

According to ImmunityBio, thousands of vials of rBCG are now available and will be shipped through the expanded access program. The US Food and Drug Administration (FDA) has authorized an expanded ...

Upon securing FDA approval, IBRX said supplies of rBCG have been shipped immediately. The alternative source was developed by the Serum Institute of India, the world’s largest manufacturer of ...

The recombinant BCG (rBCG) vaccine, developed by the Serum Institute of India, demonstrated improved immunogenicity and safety in European clinical trials for non-muscle invasive bladder cancer (NMIBC ...

The Serum Institute of India-developed alternative BCG (rBCG) source has shown promising outcomes in European clinical trials, demonstrating potent immunogenicity with cluster of differentiation 8+ ...

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication. The FDA has approved an expanded access program that will provide an alternative ...